Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CC-671 是一种双重 TTK 蛋白激酶/CLK2抑制剂, 对于 TTK 和 CLK2 的IC50值分别为 0.005 和 0.006 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 495 | 现货 | ||
5 mg | ¥ 1,160 | 现货 | ||
10 mg | ¥ 1,890 | 现货 | ||
25 mg | ¥ 3,820 | 现货 | ||
50 mg | ¥ 5,550 | 现货 | ||
100 mg | ¥ 7,770 | 现货 | ||
500 mg | ¥ 15,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,290 | 现货 |
产品描述 | CC-671 is a dual TTK protein kinase (IC50: 0.005 μM) /CLK2 (IC50: 0.006 μM) inhibitor. |
靶点活性 | CLK2:0.006 μM, TTK:0.005 μM |
体外活性 | HCT-116细胞裂解物经3 μM的CC-671处理1小时后的结果表明,仅有四种激酶展示了75%或更高的细胞结合量,包括CLK2、CAMKK2、PIP4K22和JNK[1]。 |
体内活性 | CC-671 demonstrates significant tumor growth inhibition ((vehicle -treated/vehicle) ×100%) of 71% at both 10 and 20 mg/kg on a every 3 days (q3d) dosing schedule. The body weight loss in the CC-671 treated group (20 mg/kg ) is higher than in the 10 mg/kg group (17% vs 5%)[1]. |
激酶实验 | The kinase selectivity profile of CC-671 is assessed. The screen is conducted with the concentration of CC-671 held constant at 3 μM. The TTK binding affinity is measured using the kinase binding assays. The kinase binding assays are based on the binding and displacement of a proprietary, Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor scaffold[1]. |
动物实验 | Female SCID mice are inoculated subcutaneously with 5×106 Cal-51 cells. Mice with tumours of approximately 125 mm3 are randomized and treated intravenously at various doses and schedules of CC-671 (n=8 to10/group). Tumours are measured twice a week for the duration of the study. The long and short axes of each a tumour are measured using a digital calliper in millimetres and the tumour volumes are calculated[1]. |
分子量 | 512.56 |
分子式 | C28H28N6O4 |
CAS No. | 1618658-88-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (97.55 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.951 mL | 9.755 mL | 19.5099 mL | 48.7748 mL |
5 mM | 0.3902 mL | 1.951 mL | 3.902 mL | 9.755 mL | |
10 mM | 0.1951 mL | 0.9755 mL | 1.951 mL | 4.8775 mL | |
20 mM | 0.0975 mL | 0.4877 mL | 0.9755 mL | 2.4387 mL | |
50 mM | 0.039 mL | 0.1951 mL | 0.3902 mL | 0.9755 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CC-671 1618658-88-0 Cell Cycle/Checkpoint Others CDK Inhibitor inhibit Cyclin dependent kinase CC 671 CC671 inhibitor